Kate Surdez
Human Resources Officer en MIMEDX GROUP, INC. .
Perfil
Kate Surdez is currently the Chief Human Resources Officer at MiMedx Group, Inc. She previously worked as a Global Director at AstraZeneca PLC, Director-Human Resources at Frederick Manufacturing Corp., Senior Vice President & Head-Human Resources at Viela Bio, Inc., and Vice President-People at Vaxxinity, Inc. She obtained an undergraduate degree from The University of North Carolina at Wilmington.
Cargos activos de Kate Surdez
Empresas | Cargo | Inicio |
---|---|---|
MIMEDX GROUP, INC. | Human Resources Officer | 18/07/2022 |
Antiguos cargos conocidos de Kate Surdez.
Empresas | Cargo | Fin |
---|---|---|
VAXXINITY, INC. | Human Resources Officer | - |
ASTRAZENECA PLC | Corporate Officer/Principal | - |
Frederick Manufacturing Corp. | Human Resources Officer | - |
VIELA BIO, INC. | Human Resources Officer | - |
Formación de Kate Surdez.
The University of North Carolina at Wilmington | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 3 |
---|---|
ASTRAZENECA PLC | Health Technology |
VAXXINITY, INC. | Health Technology |
MIMEDX GROUP, INC. | Health Technology |
Empresas privadas | 2 |
---|---|
Frederick Manufacturing Corp. | Producer Manufacturing |
Viela Bio, Inc.
Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |
- Bolsa de valores
- Insiders
- Kate Surdez